Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA - PubMed (original) (raw)
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Sam Chen et al. J Control Release. 2016.
Abstract
Lipid nanoparticles (LNP) can provide a clinically effective method for delivering small interfering RNA (siRNA) to silence pathological genes in hepatocytes. The gene silencing potency of these LNP-siRNA systems has been shown to depend on a variety of factors including association with serum factors such as ApoE and the pKa of component ionizable lipids. Here we investigate the influence of LNP size, an important parameter affecting tissue penetration of LNP systems, on the pharmacokinetics, biodistribution, and hepatic gene silencing potency of LNP-siRNA systems following intravenous administration. For LNP systems stabilized by a polyethylene glycol (PEG)-lipid that can dissociate from the LNP following injection, it is shown that small (diameter≤30nm) systems are considerably less potent than their larger counterparts. This is attributed in part to the ability of other lipid components, particularly the ionizable amino-lipid, to dissociate from the LNP following dissociation of the PEG-lipid. Small LNP stabilized by PEG-lipids with slow dissociation rates exhibited much reduced amino-lipid dissociation rates, however such systems are relatively impotent due to the continued presence of the PEG coating. These results demonstrate the delicate balance between the in vivo potency of LNP-siRNA systems and the residence times of component lipids in the LNP particle itself and suggest new directions to optimize the in vivo gene silencing potency of small LNP-siRNA systems.
Keywords: Drug delivery; Lipid exchange; Lipid nanoparticles; Liposomes; Nanomedicine; siRNA.
Copyright © 2016. Published by Elsevier B.V.
Similar articles
- Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S, Tam YY, Lin PJ, Leung AK, Tam YK, Cullis PR. Chen S, et al. J Control Release. 2014 Dec 28;196:106-12. doi: 10.1016/j.jconrel.2014.09.025. Epub 2014 Oct 5. J Control Release. 2014. PMID: 25285610 - Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR. Basha G, et al. Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4. Mol Ther. 2011. PMID: 21971424 Free PMC article. - On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.
Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, Tam YYC, Cullis PR. Kulkarni JA, et al. ACS Nano. 2018 May 22;12(5):4787-4795. doi: 10.1021/acsnano.8b01516. Epub 2018 Apr 6. ACS Nano. 2018. PMID: 29614232 - Lipid Nanoparticle Systems for Enabling Gene Therapies.
Cullis PR, Hope MJ. Cullis PR, et al. Mol Ther. 2017 Jul 5;25(7):1467-1475. doi: 10.1016/j.ymthe.2017.03.013. Epub 2017 Apr 13. Mol Ther. 2017. PMID: 28412170 Free PMC article. Review. - Lipid nanoparticles for short interfering RNA delivery.
Leung AK, Tam YY, Cullis PR. Leung AK, et al. Adv Genet. 2014;88:71-110. doi: 10.1016/B978-0-12-800148-6.00004-3. Adv Genet. 2014. PMID: 25409604 Free PMC article. Review.
Cited by
- Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects.
Liu Y, Huang Y, He G, Guo C, Dong J, Wu L. Liu Y, et al. Int J Mol Sci. 2024 Sep 22;25(18):10166. doi: 10.3390/ijms251810166. Int J Mol Sci. 2024. PMID: 39337651 Free PMC article. Review. - Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery.
Haque MA, Shrestha A, Mikelis CM, Mattheolabakis G. Haque MA, et al. Int J Pharm X. 2024 Sep 10;8:100283. doi: 10.1016/j.ijpx.2024.100283. eCollection 2024 Dec. Int J Pharm X. 2024. PMID: 39309631 Free PMC article. Review. - Synthesis and bioactivity of a novel surfactin-based lipopeptide for mRNA delivery.
Alqahtani MS, Syed R, Alqahtani AS, Almarfadi OM, Roni MA, Sadhu SS. Alqahtani MS, et al. Nanoscale Adv. 2024 Sep 4;6(20):5193-206. doi: 10.1039/d4na00404c. Online ahead of print. Nanoscale Adv. 2024. PMID: 39247856 Free PMC article. - Supramolecular assembly of polycation/mRNA nanoparticles and in vivo monocyte programming.
Hu Y, Tzeng SY, Cheng L, Lin J, Villabona-Rueda A, Yu S, Li S, Schneiderman Z, Zhu Y, Ma J, Wilson DR, Shannon SR, Warren T, Rui Y, Qiu C, Kavanagh EW, Luly KM, Zhang Y, Korinetz N, D'Alessio FR, Wang TH, Kokkoli E, Reddy SK, Luijten E, Green JJ, Mao HQ. Hu Y, et al. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2400194121. doi: 10.1073/pnas.2400194121. Epub 2024 Aug 22. Proc Natl Acad Sci U S A. 2024. PMID: 39172792 - Advances in the study of LNPs for mRNA delivery and clinical applications.
Wang B, Shen B, Xiang W, Shen H. Wang B, et al. Virus Genes. 2024 Aug 22. doi: 10.1007/s11262-024-02102-6. Online ahead of print. Virus Genes. 2024. PMID: 39172354 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous